{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:40:46Z","timestamp":1791038446829,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.amjcard.2004.08.076","type":"journal-article","created":{"date-parts":[[2004,12,24]],"date-time":"2004-12-24T10:45:12Z","timestamp":1103885112000},"page":"120-122","source":"Crossref","is-referenced-by-count":329,"title":["Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin"],"prefix":"10.1016","volume":"95","author":[{"given":"Peter H.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2004.08.076_bib1","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.amjcard.2004.08.076_bib2","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1124\/jpet.301.3.1042","article-title":"Mechanistic studies on metabolic interactions between gemfibrozil and statins","volume":"301","author":"Prueksaritanont","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2004.08.076_bib3","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1124\/dmd.30.12.1352","article-title":"Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes","volume":"30","author":"Wang","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.amjcard.2004.08.076_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00125-003-1034-7","article-title":"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide","volume":"46","author":"Niemi","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2004.08.076_bib5","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00125-003-1181-x","article-title":"Gemfibrozil considerably increases the plasma concentrations of rosiglitazone","volume":"46","author":"Niemi","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.amjcard.2004.08.076_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.0306-5251.2003.01862.x","article-title":"CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide","volume":"56","author":"Bidstrup","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2004.08.076_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2125.1999.00030.x","article-title":"Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone","volume":"48","author":"Baldwin","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2004.08.076_bib8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0009-9236(03)00052-3","article-title":"Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance","volume":"73","author":"Kyrklund","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2004.08.076_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mcp.2001.115542","article-title":"Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate","volume":"69","author":"Kyrklund","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2004.08.076_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mcp.2002.128469","article-title":"Gemfibrozil greatly increases plasma concentrations of cerivastatin","volume":"72","author":"Backman","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2004.08.076_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2004.08.076_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00041433-200208000-00009","article-title":"The myotoxicity of statins","volume":"13","author":"Evans","year":"2002","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2004.08.076_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(96)00742-4","article-title":"The efficacy and six-week tolerability of simvastatin 80 and 160 mg\/day","volume":"79","author":"Davidson","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2004.08.076_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2004.08.076_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/13543784.11.1.125","article-title":"Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia","volume":"11","author":"Davidson","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"issue":"suppl","key":"10.1016\/j.amjcard.2004.08.076_bib16","doi-asserted-by":"crossref","first-page":"50K","DOI":"10.1016\/S0002-9149(02)02970-3","article-title":"Combination therapy for dyslipidemia: safety and regulatory considerations","volume":"90","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2004.08.076_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/00912700022008874","article-title":"Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers","volume":"40","author":"Pan","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2004.08.076_bib18","first-page":"311","article-title":"Rhode Island physicians' recognition and reporting of adverse drug reactions","volume":"70","author":"Scott","year":"1987","journal-title":"R I Med J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914904014602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914904014602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T20:41:01Z","timestamp":1549572061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914904014602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0002914904014602"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2004.08.076","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}